Johnson & Johnson (JNJ)vsSurrozen Inc (SRZN)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
SRZN
Surrozen Inc
$29.46
-2.93%
HEALTHCARE · Cap: $275.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 862857% more annual revenue ($99.33B vs $11.51M). JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
SRZN
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Margin of Safety
-56.3%
Fair Value
$15.74
Current Price
$29.46
$13.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Revenue surging 408.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -62.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : SRZN
The strongest argument for SRZN centers on Revenue Growth, Debt/Equity. Revenue growth of 408.6% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : SRZN
The primary concerns for SRZN are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SRZN is a hypergrowth play — different risk/reward profiles.
SRZN carries more volatility with a beta of 0.47 — expect wider price swings.
SRZN is growing revenue faster at 408.6% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 32/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Surrozen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform, which is designed to modulate targeted immune responses. The company's promising pipeline includes novel antibody therapeutics aimed at treating serious oncological and autoimmune disorders, addressing critical unmet medical needs. With a strong focus on research and development, coupled with strategic partnerships, Surrozen is well-positioned to deliver transformative therapies, offering significant potential for growth and a meaningful impact within the biopharmaceutical landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?